Anacetrapib
Anacetrapib has been studied in 2 papers since 2025: none in people yet, 2 reviews; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Oct 26, 2026: “Heterogeneous biomarker responses to CETP inhibitors: a phase 3 trials systematic review and network meta-analysis”.
1 new paper in 30 daysSee all 4
None of its findings points the other way.
- 2 independent labs in 2 countries
What did studies of Anacetrapib find?
5Studies of Anacetrapib measured 5 outcomes; the most studied are C-reactive protein (1 study), lipoprotein (1) and high-density lipoprotein cholesterol (1).
C-reactive protein
upin humans1
1 study
C-reactive protein
upin humans1
Anacetrapib increases C-reactive protein in humans (MD 16.85%; 95% CI 9.79 to 23.92).
“CRP increased versus placebo with anacetrapib (MD 16.85%; 95% CI 9.79 to 23.92) and evacetrapib (MD 8.60%; 95% CI 6.29 to 10.91)”
Reviewversus placebo
ESC Congress 2026 abstract
Lipoprotein
downin humans1
1 study
Lipoprotein
downin humans1
Anacetrapib decreases lipoprotein in humans (MD −39.05 nmol/L; 95% CI −52.49 to −25.60).
“For lipoprotein(a), anacetrapib reduced Lp(a) (MD −39.05 nmol/L; 95% CI −52.49 to −25.60)”
Reviewversus placebo
ESC Congress 2026 abstract
High-density lipoprotein cholesterol
upin humans1
1 study
High-density lipoprotein cholesterol
upin humans1
Anacetrapib increases high-density lipoprotein cholesterol in humans (MD 125.13 mg/dL; 95% CI 106.31 to 143.95).
“HDL-C increased substantially with anacetrapib (MD 125.13 mg/dL; 95% CI 106.31 to 143.95)”
Reviewversus placebo
ESC Congress 2026 abstract
Low-density lipoprotein cholesterol
downin humans1
1 study
Low-density lipoprotein cholesterol
downin humans1
Anacetrapib decreases low-density lipoprotein cholesterol in humans (MD −37.14 mg/dL; 95% CI −39.01 to −35.26).
“For LDL-C, anacetrapib (MD −37.14 mg/dL; 95% CI −39.01 to −35.26) and evacetrapib (MD −37.10 mg/dL; 95% CI −38.22 to −35.98) produced the largest reductions”
Reviewversus placebo
ESC Congress 2026 abstract
LDL cholesterol
downin humans1
1 study
LDL cholesterol
downin humans1
Anacetrapib decreases LDL cholesterol in humans (MD -30.18 mg/dL, 95% CI [-39.28; -21.08]).
“Both Anacetrapib and Obicetrapib demonstrated significant LDL cholesterol reductions compared to placebo (Anacetrapib: MD -30.18 mg/dL, 95% CI [-39.28; -21.08], p < 0.0001”
Reviewcompared to placebo
ENDO 2025 abstract